JNJ-26481585 CAS: 875320-29-9
MF: C21H26N6O2
MW: 394.5
An HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11 inhibitor.

JNJ-26481585 (CAS 875320-29-9)

JNJ-26481585 | CAS 875320-29-9 is rated 5.0 out of 5 by 1.
  • y_2020, m_11, d_30, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364515, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 126ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Quisinostat
Application: JNJ-26481585 is an HDAC1, HDAC2, HDAC4, HDAC10, and HDAC11 inhibitor
CAS Number: 875320-29-9
Molecular Weight: 394.5
Molecular Formula: C21H26N6O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

JNJ-26481585 (Quisinostat) is an HDAC inhibitor. It has a second generation histone deacetylase inhibitor with antineoplastic activities. It inhibits well for HDAC1 (IC50 = 0.11 nM), HDAC2 (IC50 = 0.33 nM), HDAC4 (IC50 = 0.64 nM), HDAC10 (IC50 = 0.46 nM), HDAC11 (IC50 = 0.37 nM).

Physical State :
Solid
Solubility :
Soluble in DMSO (79 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), ethanol (<1 mg/ml at 25 °C), and 15% Captisol (30 mg/ml at 25 °C).
Storage :
Store at -20° C
Melting Point :
276.22° C (Predicted)
Boiling Point :
636.19° C (Predicted)
Density :
~1.4 g/cm3 (Predicted)
Refractive Index :
n20D 1.69 (Predicted)
IC50 :
HDAC1: IC50 = 0.11 nM; HDAC2: IC50 = 0.33 nM; HDAC11: IC50 = 0.37 nM; HDAC10: IC50 = 0.46 nM; HDAC4: IC50 = 0.64 nM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
11538455
SMILES :
CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 106ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Schreml Schreml, J. et al. (PubMed 23073311) reported that severe spinal muscular atrophy mice show organ impairment that cannot be rescued by therapy with the HDAC inhibitor JNJ-26481585. -SCBT Publication Review
Date published: 2015-07-02
  • y_2020, m_11, d_30, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.12
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364515, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 7ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.